



US008791154B2

(12) **United States Patent**
Gamache et al.

(10) **Patent No.:** **US 8,791,154 B2**
(45) **Date of Patent:** **Jul. 29, 2014**

(54) **HIGH CONCENTRATION OLOPATADINE
OPHTHALMIC COMPOSITION**

(75) Inventors: **Daniel A. Gamache**, Arlington, TX
(US); **Laman Alani**, Fort Worth, TX
(US); **Malay Ghosh**, Fort Worth, TX
(US); **Francisco Javier Galán**,
Barcelona (ES); **Núria Carreras**
Perdiguer, Barcelona (ES); **Onkar N.**
Singh, Arlington, TX (US)

(73) Assignee: **Alcon Research, Ltd.**, Fort Worth, TX
(US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 1 day.

(21) Appl. No.: **13/475,607**

(22) Filed: **May 18, 2012**

(65) **Prior Publication Data**

US 2012/0295967 A1 Nov. 22, 2012

Related U.S. Application Data

(60) Provisional application No. 61/487,789, filed on May
19, 2011, provisional application No. 61/548,957,
filed on Oct. 19, 2011.

(51) **Int. Cl.**

A61K 31/335 (2006.01)
A61K 47/48 (2006.01)
C08B 37/16 (2006.01)
C08L 5/16 (2006.01)
A61K 9/08 (2006.01)
A61K 9/00 (2006.01)
A61K 47/32 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/335** (2013.01); **A61K 47/48969**
(2013.01); **C08B 37/0015** (2013.01); **C08L 5/16**
(2013.01); **A61K 47/32** (2013.01); **A61K 9/08**
(2013.01); **A61K 9/0048** (2013.01)
USPC **514/450**; 514/449

(58) **Field of Classification Search**

USPC 514/449, 450
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,767,788 A 10/1973 Rankin
3,843,782 A 10/1974 Krezanoski et al.
3,856,919 A 12/1974 Rankin
3,931,319 A 1/1976 Green et al.
3,947,573 A 3/1976 Rankin
4,027,020 A 5/1977 Green et al.
4,120,949 A 10/1978 Bapatla et al.
4,283,393 A 8/1981 Field et al.
4,407,791 A 10/1983 Stark

4,836,986 A 6/1989 Ogunbiyi et al.
4,923,693 A 5/1990 Michalos
5,037,647 A 8/1991 Chowhan et al.
5,068,225 A 11/1991 Pennell et al.
5,116,863 A 5/1992 Oshima et al.
5,134,127 A 7/1992 Stella et al.
5,141,961 A 8/1992 Coapman
5,300,287 A 4/1994 Park
5,376,645 A 12/1994 Stella et al.
5,472,954 A 12/1995 Lofsson
5,591,426 A 1/1997 Dabrowski et al.
5,597,559 A 1/1997 Olejnik et al.
5,624,962 A 4/1997 Takeuchi et al.
5,641,805 A * 6/1997 Hayakawa et al. 514/450
5,874,414 A 2/1999 Haseloff et al.
5,874,418 A * 2/1999 Stella et al. 514/58
5,888,493 A 3/1999 Sawaya
6,153,746 A 11/2000 Shah et al.
6,280,745 B1 8/2001 Flore et al.
6,407,079 B1 6/2002 Muller et al.
6,511,949 B1 1/2003 Nitta et al.
6,828,356 B2 12/2004 Su et al.
6,995,186 B2 * 2/2006 Castillo et al. 514/450
7,074,424 B2 7/2006 Avila et al.
7,147,844 B2 12/2006 Hamano et al.
7,429,602 B2 9/2008 Trach et al.
7,635,773 B2 12/2009 Antle
2002/0006443 A1 1/2002 Curatolo et al.
2002/0150616 A1 10/2002 Vandecruys
2003/0170309 A1 9/2003 Babcock et al.
2004/0198828 A1 * 10/2004 Abelson et al. 514/571
2005/0004074 A1 1/2005 Lyons et al.
2005/0191270 A1 9/2005 Gruening et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2 391 076 5/2001
EP 1 004 309 5/2000

(Continued)

OTHER PUBLICATIONS

Chigbu, "The management of allergic eye disease in primary eye
care", Contact Lens & Anterior Eye, 32, pp. 260-272, 2009.
Chigbu, "The pathophysiology of ocular allergy: A review", Contact
Lens & Anterior Eye, 32, pp. 3-15, 2009.
Ciprandi et al., "Cetirizine reduces inflammatory cell recruitment and
ICAM-1 (or CD54) expression on conjunctival epithelium in both
early- and late-phase reactions after allergen-specific challenge", J
Allergy Clin Immunol, vol. 95, No. 2, pp. 612-621, Feb. 1995.
Du Buske, "Clinical comparison of histamine H1-receptor antagonist
drugs", JAllergy Clin Immunol, vol. 98, No. 6, part 3, pp. S307-S318,
Dec. 1996.

(Continued)

Primary Examiner — My-Chau T Tran
(74) Attorney, Agent, or Firm — Scott A. Chapple

(57) **ABSTRACT**

The present invention is an ophthalmic composition contain-
ing a relatively high concentration of olopatadine. The com-
position is typically an ophthalmic aqueous solution contain-
ing relatively high concentrations of olopatadine solubilized
within the solution. The composition is preferably capable of
providing enhanced relief from symptoms of ocular allergic
conjunctivitis, particularly late phase symptoms of ocular
allergic conjunctivitis.

(56)

References Cited

U.S. PATENT DOCUMENTS

2005/0244472	A1	11/2005	Hughes et al.	
2006/0210645	A1	9/2006	Du Mee et al.	
2007/0020336	A1	1/2007	Lofsson et al.	
2008/0132444	A1	6/2008	Li et al.	
2009/0118262	A1	5/2009	Rohrs et al.	
2009/0232763	A1	9/2009	Kabra et al.	
2009/0239842	A1	9/2009	Trach et al.	
2010/0240625	A1	9/2010	Abelson et al.	
2010/0249062	A1	9/2010	Matsumura et al.	
2010/0324031	A1	12/2010	Kabra	
2011/0082145	A1*	4/2011	Schneider et al.	514/235.2
2012/0015953	A1*	1/2012	Beauregard et al.	514/250

FOREIGN PATENT DOCUMENTS

EP	0862414	12/2001
EP	0998304	8/2003
EP	1 231 920	2/2007
EP	1 994 931	11/2008
GB	2169508	7/1986
JP	2001-158750	6/2001
WO	88/08709	11/1988
WO	90/04971	5/1990
WO	91/09523	7/1991
WO	96/39147	12/1996
WO	01/54687	8/2001
WO	03/013481	2/2003
WO	2006/011044	2/2006
WO	2008/015695	2/2008
WO	2009/003199	12/2008
WO	2010/107689	9/2010

OTHER PUBLICATIONS

Fukuda et al., "Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis", *J Allergy Clin Immunol*, vol. 124, No. 4, 827-833.e2, Oct. 2009.

International Search Report for corresponding PCT/US2012/038663 with mailing date Jul. 25, 2012.

International Written Opinion for corresponding PCT/US2012/038663 with mailing date Jul. 25, 2012.

Izushi et al., "The role of histamine H1 receptors in late-phase reaction of allergic conjunctivitis", *European Journal of Pharmacology*, 440:79-82, 2002.

Leonardi and Abelson, "Double-Masked, Randomized, Placebo-Controlled Clinical Study of the Mast Cell-Stabilizing Effects of Treatment with Olopatadine in the Conjunctival Allergen Challenge Model in Humans", *Clinical Therapeutics*, vol. 25, No. 10, pp. 2539-2552, 2003.

Ozaki et al., "Mast-cell activation augments the late phase reaction in experimental immune-mediated blepharoconjunctivitis", *Graefes Arch Clin Exp Ophthalmol*, 241:394-402, 2003.

Ueta et al., letter to editor, "Development of eosinophilic conjunctival inflammation at late-phase reaction in mast cell-deficient mice", *J Allergy Clin Immunol*, pp. 476-478, Aug. 2007.

Vogelsson et al., "Preclinical and Clinical Antiallergic Effect of Olopatadine 0.2% Solution 24 Hours after Topical Ocular Administration", *Allergy and Asthma Proc.*, vol. 25, No. 1, pp. 69-75, Jan.-Feb. 2004.

Yanni et al., "The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), an Effective Anti-Allergic/Antihistaminic Agent", *Journal of Ocular Pharmacology and Therapeutics*, vol. 12, No. 4, 1996.

International Preliminary Report on Patentability for corresponding PCT/US2012/038663 with mailing date Nov. 28, 2013.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.